Toronto-based
Avicanna Inc. (TSX: AVCN, OTCQX: AVCNF, Forum) announced on Wednesday that it had entered into an
exclusive intellectual property licensing and royalty agreement with
Heritage Cannabis Holdings Corp. for the commercialization of a number of Avicanna’s advanced CBD-based topical products under Heritage’s medical cannabis brands targeting patients registered to purchase medical cannabis in Canada.
The biopharmaceutical company developing and driving biopharmaceutical advancements of plant-derived cannabinoid-based products, is advancing its proprietary cannabinoid topical formulations. The specific products are all supported with pre-clinical studies in addition to two of the SKUs that are supported by completed human studies. The branded products are planned to launch by Q4 2021.
Avicanna’s Chief Executive Officer, Aras Azadian said that this collaboration will extend the company’s proprietary and evidence-based topical formulations to more Canadian patients and expand into more medical channels nationwide.
“We believe that the alignment of both companies to offer the highest standards for cannabinoid-based medicine and education will yield fruitful and long-term commercial success.”
Complete article
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.
FULL DISCLOSURE: Avicanna Inc. is a client of Stockhouse Publishing.